P, A., E, G., C, F., E, R., M, F. d. l. M., J, D., . . . F, B. (2024). Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).
Citación estilo ChicagoP, Abrisqueta, et al. Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL): GELLC-7 Trial From the Spanish Group of CLL (GELLC). 2024.
Cita MLAP, Abrisqueta, et al. Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL): GELLC-7 Trial From the Spanish Group of CLL (GELLC). 2024.
Precaución: Estas citas no son 100% exactas.